NCT04800822 2024-10-22PF-07284892 in Participants With Advanced Solid TumorsPfizerPhase 1 Terminated53 enrolled
NCT05764915 2024-08-01A Phase I Study of RGT-264 in Subjects With Advanced Solid TumorsRegor Pharmaceuticals Inc.Phase 1 Terminated11 enrolled
NCT04586335 2024-03-21Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.Haihe Biopharma Co., Ltd.Phase 1 Terminated24 enrolled
NCT02292225 2023-02-27Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)SecuraBioPhase 1 Terminated3 enrolled
NCT04330625 2022-11-08Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)Duke UniversityPhase 1 Terminated1 enrolled
NCT03074825 2019-07-24Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's LymphomaChipscreen Biosciences, Ltd.Phase 1 Terminated5 enrolled